Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory [Yahoo! Finance]
Capricor Therapeutics, Inc. (CAPR)
Last capricor therapeutics, inc. earnings: 3/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
capricor.com/investors
Company Research
Source: Yahoo! Finance
In this article, we will summarize the bulls' thesis on CAPR. Capricor Therapeutics, Inc.'s share was trading at $26.55 as of December 15th. Capricor Therapeutics, Inc., a clinical-stage biotechnology company, develops transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. CAPR remains a structurally challenged, chronically unprofitable biotech company whose valuation is disconnected from fundamentals. Despite years of promoting Deramiocel (CAP-1002) as a potential treatment for Duchenne muscular dystrophy (DMD), the company has yet to generate meaningful revenue, relying instead on repeated capital raises and marketing narratives to sustain operations. The FDA's Complete Response Letter (CRL) earlier this year highlighted the regulatory fragility of Deramiocel, but the market continues to assign CAPR a roughly $300 million market cap, reflecting hope rather than evidence.
Show less
Read more
Impact Snapshot
Event Time:
CAPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAPR alerts
High impacting Capricor Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CAPR
News
- Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular DystrophyGlobeNewswire
- Capricor Therapeutics (NASDAQ:CAPR) was given a new $50.00 price target on by analysts at UBS Group AG.MarketBeat
- Capricor Therapeutics (NASDAQ:CAPR) had its "buy" rating reaffirmed by analysts at B. Riley.MarketBeat
- Capricor: A Detailed Examination Of Hope-3 [Seeking Alpha]Seeking Alpha
- Capricor Therapeutics (NASDAQ:CAPR) had its "overweight" rating reaffirmed by analysts at Piper Sandler.MarketBeat
CAPR
Earnings
- 11/10/25 - In-Line
CAPR
Sec Filings
- 12/5/25 - Form 424B5
- 12/5/25 - Form 8-K
- 12/5/25 - Form 424B3
- CAPR's page on the SEC website